Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Osaka, Japan.
Division of Biostatistics, Tohoku University Graduate School of Medicine, Sendai, Japan.
Gastric Cancer. 2017 May;20(3):508-516. doi: 10.1007/s10120-016-0636-y. Epub 2016 Aug 27.
A critical issue in multicenter randomized trials focusing on surgical techniques is quality control, as the quality of the surgery usually varies widely if the procedure employed is complicated. Few studies have evaluated interinstitutional variation in randomized trials in order to check not only the generalizability of the results but also the reliability of the study group itself.
Two randomized phase III trials (JCOG9501 and JCOG9502) were conducted that compared standard and experimental surgery for gastric and esophagogastric junction adenocarcinomas. Mixed effects models were used to examine short- and long-term outcome data for 521 patients from 23 hospitals in JCOG9501 and 157 patients from 21 hospitals in JCOG9502.
In both trials, some variation was observed in the number of dissected lymph nodes, the operative time, and the volume of blood lost. Estimated 5-year overall survival after standard surgery differed among hospitals (JCOG9501, 58.0-75.1 %; JCOG9502, 49.1-58.7 %), while there was little variation in the hazard ratio for overall survival (OS) for experimental versus standard surgery (JCOG9501, 1.05-1.48; JCOG9502, 1.44-1.48). Higher hospital gastrectomy volume was significantly correlated with a lower proportion of postoperative complications in JCOG9501 (ρ = -0.524, P = 0.010) and reduced blood loss in JCOG9502 (ρ = -0.442, P = 0.045). OS was not correlated with hospital or surgeon volume.
There was some degree of interinstitutional variation in outcomes after standard surgery, but there was little variation in the hazard ratio for OS for experimental surgery, indicating that the final conclusions of the two randomized phase III trials can be generalized to their respective target populations.
在关注手术技术的多中心随机试验中,一个关键问题是质量控制,因为如果所采用的手术复杂,手术质量通常差异很大。很少有研究评估随机试验中的机构间差异,以便不仅检查结果的可推广性,还检查研究组本身的可靠性。
进行了两项比较胃和食管胃交界腺癌标准和实验性手术的随机 III 期试验(JCOG9501 和 JCOG9502)。使用混合效应模型检查来自 JCOG9501 的 23 家医院的 521 例患者和 JCOG9502 的 21 家医院的 157 例患者的短期和长期结果数据。
在两项试验中,观察到淋巴结清扫数量、手术时间和失血量存在一定差异。标准手术后估计的 5 年总生存率在医院之间存在差异(JCOG9501,58.0-75.1%;JCOG9502,49.1-58.7%),而实验性手术与标准手术的总生存危险比(OS)变化不大(JCOG9501,1.05-1.48;JCOG9502,1.44-1.48)。JCOG9501 中,医院胃切除术量较高与术后并发症比例较低显著相关(ρ=-0.524,P=0.010),JCOG9502 中,与失血量减少相关(ρ=-0.442,P=0.045)。OS 与医院或外科医生的手术量无关。
标准手术后的结果存在一定程度的机构间差异,但实验性手术的 OS 危险比变化不大,表明这两项随机 III 期试验的最终结论可以推广到各自的目标人群。